All Oncology News

The combination of the immunotherapy CRS-207 and the vaccine GVAX Pancreas has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic pancreatic cancer.

Many specialists are balking at what they say are onerous new rules to get recertified, warning the demands will force some physicians out of practice at a time when the nation faces a shortage.

A phase III study comparing trametinib (Mekinist) plus dabrafenib (Tafinlar) with single-agent vemurafenib (Zelboraf) has been stopped early following a positive interim analysis

A gel formulation of tamoxifen is equally as effective with fewer side effects when compared with oral tamoxifen in women with ductal carcinoma in situ.

The somatostatin analog lanreotide (Somatuline Depot) significantly prolonged progression-free survival (PFS) compared with placebo for patients with metastatic gastroenteropancreatic neuroendocrine tumors.

Memorial Sloan Kettering Cancer Center is proud and honored to announce it has been named the number one hospital for cancer care in the nation.

The FDA has assigned a priority review designation to bevacizumab (Avastin) plus chemotherapy as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.

As the use of electronic patient portals grows, a new study examines the use of these portals by cancer patients, extending the doctor-patient relationship to new boundaries.

Patients with small, node-negative, HER2-positive breast cancer tumors had a low risk of invasive recurrence after 5 years

Leading experts from renowned academic centers join in one voice to encourage new perspectives in addressing brain cancer

Surgical Team at NYU Langone Medical Center Successfully Removes Life-Threatening Retroperitoneal Mass Along with Several Organs -- Staten Island Resident Expresses His Thanks

The combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib significantly improved PFS compared with vemurafenib alone for patients with untreated BRAFV600-mutated advanced melanoma.

A pilot program that paid oncologists upfront for the patient's full treatment program regardless of the drugs administered resulted in a 34% reduction in medical costs.

Cardiac events associated with trastuzumab are mostly reversible and outweighed by significant extensions in OS and PFS for patients with HER2-positive breast cancer, according to analyses from several clinical trials exploring the drug.

The investigational CD19-targeted CAR therapy CTL019 has received a breakthrough therapy designation from the FDA as a potential treatment for pediatric and adult patients with relapsed/refractory ALL.

North Carolina's only public NCI-designated comprehensive cancer center will work with OncLive to educate the oncology community on ongoing cancer prevention, treatment, and research programs.

The PD-1 inhibitor nivolumab and the second-generation ALK inhibitor alectinib have each gained their first approvals as treatments for patients in Japan.

With the uncertainty that accompanies health reform, a safe and secure alignment that integrates oncologists with a hospital or academic medical center can be seductive.

The FDA has approved belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

The FDA has granted a breakthrough therapy designation to blinatumomab for the treatment of adult patients with Philadelphia-negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)

A new survey by McKesson Health Solutions and released at America's Health Insurance Plan's Institute 2014 conference examined the state of value-based reimbursement, and found that of the existing value-based models, payers and hospitals/health systems predict pay-for-performance (P4P) will experience the most growth

Patricia M. LoRusso, DO, widely-regarded as a leading expert on developing new cancer drugs through clinical trials, will join Yale Cancer Center in August as a Professor of Medicine and Associate Director of Innovative Medicine at Yale Cancer Center.

Ofatumumab (Arzerra) failed to meet its primary endpoint of improvement in progression-free survival (PFS) in a phase III study of the drug versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukemia (CLL),

The FDA's Oncologic Drugs Advisory Committee voted 11-2 against the accelerated approval of the PARP inhibitor olaparib as a maintenance therapy for women with platinum-sensitive relapsed ovarian cancer with germline BRCA mutations.

Frontline treatment with the anti-PD-1 agent nivolumab significantly extended overall survival when compared with dacarbazine for patients with metastatic or unresectable melanoma.

Hospitals, community health centers, and clinics that participate in the federal 340B drug pricing program are finding themselves under scrutiny from some members of Congress and the pharmaceutical industry because of recent expansion of the Affordable Care Act.

Some health plans and clearinghouses are charging unreasonable fees for electronic fund transfer (EFT) transactions to providers who accept payment from virtual credit cards

The FDA has issued a drug safety communication regarding the risk of intoxication with the intravenous ethanol-containing chemotherapy docetaxel.

A third of practice managers and health care executives who participated in a survey about value-based contracts said they expected the agreements to hurt the bottom line of their institution or practice

A significant proportion of oncology patients and caregivers feel they are not getting the information they want from their cancer care team, and nearly 1 in 4 are dissatisfied with the care provided during their treatment journey